Custom Biomarker Assay Development

Custom Assay Development Redefined with the Flexibility of SPEAR

SPEAR Custom Assay Development services provide a flexible approach to exploring novel assays with unparalleled sensitivity, specificity, and precision. SPEAR’s two-factor-authenticated, homogeneous assay platform overcomes key obstacles in custom immunoassay development, including low target abundance and reagent affinity.

Our custom assay services deliver robust, reproducible results, empowering you to unlock new insights and potentially discover the next impactful biomarker in your field.

0.25 μL sample requirement allows fit-for-purpose testing at scale

Avoid false attrition of good reagents and conditions

Why SPEAR’s Flexible Assay Design Matters
in Custom Assay Development

Traditional immunoassay development depends on the affinity of antibody pairs to achieve adequate sensitivity—especially after multiple wash steps that can compromise immunocomplex stability. This requirement significantly limits the feasibility of custom assay development, particularly for targets with limited antibody availability.

SPEAR technology removes this barrier. Its homogeneous, wash-free assay format preserves immunocomplex integrity, improves binding kinetics, and eliminates the signal loss associated with traditional wash steps. Combined with our proprietary two-factor detection system, SPEAR enables custom immunoassays with exceptional sensitivity—even when using moderate- or low-affinity antibodies.

This flexibility is a defining advantage of the SPEAR platform. It empowers researchers to pursue bespoke assay design more efficiently, expanding what’s possible in biomarker assay development without compromising quality or reproducibility.

Overcome Conventional Limits in Biomarker Discovery with SPEAR Custom Assays

Designed for researchers pushing the boundaries of what’s measurable, SPEAR Custom Assay Development transforms ambitious ideas into actionable data. Our scientific team partners with researchers to overcome the challenges that have traditionally made it difficult to develop reliable assays for novel biomarkers—including reagent compatibility, low target abundance, and platform limitations—advancing your research with confidence.

Assay Development Services to Drive Innovation

SPEAR delivers what conventional platforms can’t:

Successive Proximity Extension Amplification Reaction (SPEAR) technology allows you to unlock untapped opportunities to study novel low-abundance proteins and advance scientific understanding in your discipline.

SPEAR’s two-factor authentication and surface-free binding virtually eliminate false positives—critical for custom immunoassays where cross-reactivity is a common challenge.

Unlike conventional immunoassays, SPEAR’s unique assay design enables reliable signal generation even with moderate- or low-affinity antibodies—broadening assay feasibility and reducing development constraints.

SPEAR’s robust, wash-free workflow consistently achieves mean CVs of less than 5%, providing the reliability needed to develop custom assays that scale confidently across diverse study types and sample sets.

Our SPEAR platform enables exceptional assay performance using just 1 µL of diluted sample—ideal for custom assay projects where sample availability is limited. Its streamlined, wash-free workflow reduces hands-on time and leverages widely available qPCR instrumentation.

The SPEAR Custom Assay Development Process: From Sample to Insight

SPEAR Custom Assay Development is a collaborative, expert-guided process designed to help you build high-performance immunoassays around your unique targets. You bring the research question, reagents, or antibodies and our team works closely with you to design, optimize, and validate the assay. The flexibility and robustness of the SPEAR platform eliminate many of the typical barriers to immunoassay development, enabling faster progress toward reliable and impactful data. These immunoassay development services enable precise quantification for novel biomarker discovery and support early-stage biomarker development services.